Market Leadership Crown Bioscience’s recognition as the Best Preclinical Oncology CRO and its extensive oncology-focused research platforms position it as a leader in the preclinical drug development space, offering growth opportunities through strategic partnerships and service expansion.

Global Presence Operating across 11 state-of-the-art facilities in the US, Europe, and APAC enables CrownBio to serve diverse markets and provides an excellent opportunity to target multinational biotech and pharma clients seeking reliable CRO partners worldwide.

Recent Acquisition Momentum The upcoming acquisition by Adicon Clinical Laboratories highlights growth potential and increased industry consolidation, making CrownBio an attractive target for collaborative ventures or additional investments to expand service offerings.

Innovative Technologies With capabilities like the world’s largest PDX collection and advanced tumor organoid models, CrownBio offers innovative preclinical research solutions that can address unmet client needs, creating prospects for customized service packages.

Financial and Industry Position Generating between $100 million and $250 million in revenue with significant funding, CrownBio demonstrates solid financial health and a scalable platform, providing a foundation for upselling emerging service lines and integrated solutions to existing clients.